Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Shiyuan Hong has a total of 69 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Gender-Neutral Human Papillomavirus (HPV) Vaccination in Men: A Mixed-Methods Data Synthesis Leveraging Empirical Prevalence and Cost-Effectiveness Evidence

    by Wenzhen Wei, Gary M. Clifford, Jason J. Ong, Sten H. Vermund, Xianglin Guo, Tom Nadarzynski, Anna Beltrame, Anna Giuliano, Pengming Sun, Qing Cong, et al.

    Background: Human papillomavirus (HPV) is a common sexually transmitted infection that can lead to various cancers in men, including penile, anal, and oropharyngeal cancers. National HPV vaccination policies vary regarding no vaccination, female-only, or gender-neutral vaccination, and the direct benefit of vaccinating men is understudied. Empirical evidence that gender-neutral vaccination lowers genital HPV prevalence in men and modelling evidence that it is cost-effective have accumulated separately but never been brought together. Methods: We did a dual-stream evidence synthesis in which two evidence streams were synthesised separately and integrated narratively. Stream 1 was a systematic review and random-effects meta-analysis (generalised linear mixed models) of genital HPV prevalence in heterosexual men in countries with prevalence data under three policies: no vaccination, female-only, and gender-neutral. For Stream 2, we classified each cost-effectiveness study by the direction of its own conclusion for gender-neutral vaccination versus its comparator (female-only vaccination, no vaccination, or screening only) and tested the counts with an exact binomial sign test. Both streams address the same population-exposure axis: heterosexual men and genital HPV. Findings: Stream 1 included 18 studies (21 observations; 7,661 men) from the USA, Canada, and Australia; studies were published between 1995 and 2025. Gender-neutral vaccination was associated with lower odds of vaccine-type HPV in men versus no vaccination (2v-HPV odds ratio 0·07 [95% CI 0·02–0·24], 11 observations, residual I²=74·9%; 4v-HPV 0·21 [0·08–0·59], 13 observations, I²=91·0%) and versus female-only vaccination directly (2v-HPV 0·19, 0·05–0·70). Stream 2 included 45 cost-effectiveness modelling studies across 32 countries and regions in the Americas, Europe, Asia, and Oceania, published between 2007 and 2026: 37 of the 45 (82·2%, 95% CI 68·7–90·7) concluded that gender-neutral vaccination was cost-effective relative to its comparator at that setting's stated willingness-to-pay threshold (exact binomial test against 0·5, P<0·0001). The direction was consistent across comparators (29 of 37 studies versus female-only vaccination, six of six versus no vaccination, and two of two versus screening only). Interpretation: Gender-neutral vaccination lowers vaccine-type HPV prevalence in men and is cost-effective in most modelled settings. In the modelling stream, the incremental value of adding men was largest where female coverage was low or moderate. These findings support including men in national HPV immunisation programmes, particularly where female coverage is not already high.Funding The National Natural Science Foundation of China [8257121609], the Prevention and Control of Emerging and Major Infectious Diseases-National Science and Technology Major Project [2025ZD01905200], and the National Key Technology Research and Development Programme of China [2023YFC2306700].

  • Open Access

    Oligodendrocyte transcription factor 2 orchestrates glioblastoma immune evasion by suppressing CXCL10 and CD8+ T cell activation

    by Xinchun Zhang, Jinjiang Xue, Cunyan Zhao, Chenqiuyue Zeng, Jiacheng Zhong, Gangfeng Yu, Xi Yang, Yao Ling, Dazhen Li, Jiaxiao Yang, et al.

    Glioblastoma (GBM) is a highly lethal brain tumor with limited treatment options and resistance to immune checkpoint inhibitors due to its immunosuppressive tumor microenvironment (TME). Here, we identify OLIG2 as a key regulator of immune evasion in GBM stem-like cells, inhibiting CD8+ T cell-dependent antitumor immunity, while promoting pro-tumor macrophages polarization. Mechanistically, OLIG2 recruits HDAC7 to repress CXCL10 transcription, inducing STAT3 activation in tumor-associated macrophages (TAMs) and decreasing CD8+ T cell infiltration and activation. Genetic deletion of OLIG2 significantly increases CXCL10 secretion, shifting TAMs toward an anti-tumor phenotype and enhancing CD8+ T cell activities. Furthermore, upregulated OLIG2 expression is correlated to resistance to immune checkpoint inhibitors (ICIs) in GBM patients. OLIG2 inhibition by either genetic deficiency or pharmacological targeting with CT-179 sensitizes GBM tumors to anti-PD-L1 therapy, enhancing antitumor immune responses and prolonging survival. Our findings reveal OLIG2+ glioma stem-like cells as critical mediators of immune evasion and identify the OLIG2/HDAC7/CXCL10 axis as a potential therapeutic target to enhance immune checkpoint inhibitors efficacy and to improve immunotherapy outcomes in aggressive GBM.


  • Open Access

    Topoisomerase IIα orchestrates secretion of IL-6 and IL-8 with human papillomavirus replication

    by Yanfei Liu, Zi Han, Paul Kaminski, Chengcheng Tao, Xiaoge Li, Mengmeng Liu, Yang Li, Ying Jia, Junfen Xu, Shiyuan Hong

    High-risk human papillomavirus (HPV) replication requires deregulation of host DNA damage response (DDR) and inflammatory pathways. DNA topoisomerase 2β (Top2β) was previously shown to promote HPV replication. We investigated whether its paralog Top2α protein acts similarly to the virus. Elevated levels of Top2α are consistently observed in cervical intraepithelial lesions and the related carcinomas, as well as in HPV-positive cell lines. Silencing Top2α with shRNA severely suppresses HPV genome maintenance and amplification, but in a DDR-independent manner. Instead, Top2α facilitates secretion of interleukin (IL)-6 and IL-8, which are necessary for HPV replication. Mechanistically, this manipulation is regulated by toll-like receptor 4 (TLR4). Top2α binds to the TLR4 promoter to transcriptionally induce TLR4 expression. Blockade of TLR4 signaling by the specific inhibitor TAK-242 significantly reduces the secreted IL-6/IL-8 levels and HPV replication. Overall, our results reveal a novel role of Top2α to shape the inflammatory microenvironment that benefits HPV replication, making it a promising therapeutic target for HPV-associated diseases.


  • Open Access

    Oncoproteins E6 and E7 upregulate topoisomerase I to activate the cGAS-PD-L1 pathway in cervical cancer development

    by Ying Luo, Mengda Niu, Yanfei Liu, Miaochang Zhang, Yuanyuan Deng, Dan Mu, Junfen Xu, Shiyuan Hong

    Background: Cervical cancer (CC) stands as a significant health threat to women globally, with high-risk human papillomaviruses as major etiologic agents. The DNA damage repair (DDR) protein topoisomerase I (TOP1) has been linked to various cancers, yet its distinct roles and mechanisms in CC are not fully elucidated.Methods: We investigated TOP1 expression in cervical intraepithelial neoplasia (CIN) and CC tissues utilizing qRT-PCR and IHC, correlating findings with patient prognosis. Subsequent knockdown studies were performed in vitro and in vivo to evaluate the influence of TOP1 on tumor growth, DNA repair, and inflammatory responses.Results: TOP1 was highly expressed in CIN and CC, negatively correlating with patient prognosis. Inhibition of TOP1 impeded CC cell growth and disrupted DNA repair. TOP1 was shown to regulate tumor-promoting inflammation and programmed death-ligand 1 (PD-L1) production in a cGAS-dependent manner. HPV oncoproteins E6 and E7 upregulated TOP1 and activated the cGAS-PD-L1 pathway.Conclusions: TOP1 acts as a DNA repair mediator, promoting CC development and immune evasion. Targeting the TOP1-cGAS-PD-L1 axis could be a potential therapeutic strategy for CC.


  • Open Access

    DNA damage repair factor TOP1 induces tumor-promoting inflammation and PD-L1 production via a cGAS-dependent manner during cervical cancer development

    by Shiyuan Hong, Ying Luo, Mengda Niu, Yanfei Liu, Miaochang Zhang, Yuanyuan Deng, Dan Mu, Junfen Xu

    Cervical carcinogenesis is regulated by DNA damage repair (DDR) and inflammation. The DDR protein topoisomerase I (TOP1) has been implicated in various cancers due to its role in regulating genome stability. Recent studies have revealed that TOP1 regulates the anti-inflammatory response and TOP1 inhibition protects cells from COVID-19-induced death. However, the specific functions and mechanisms of TOP1 in cervical cancer (CC) remain unclear. Here, our research highlights the crucial role of TOP1 in the regulation of cervical tumorigenesis. TOP1 is highly expressed in cervical intraepithelial neoplasia (CIN) and CC tissues, which is negatively correlated with the prognosis of CC patients. Inhibiting TOP1 suppresses CC cell growth and impairs DNA repair both in vitro and in vivo. To trigger CC development, TOP1 promotes tumor-promoting inflammation and increases production of programmed death-ligand 1 (PD-L1) in cyclic GMP-AMP synthase (cGAS)-dependent manner. Human papillomavirus (HPV) oncoproteins E6 and E7 significantly upregulate TOP1 and facilitate activation of the cGAS-PD-L1 pathway. Our research demonstrates that TOP1 serves as a DNA repair factor, induces expression of tumor-promoting inflammatory genes and activates the non-canonical cGAS-PD-L1 pathway to promote CC development. Therefore, targeting TOP1-mediated cGAS-PD-L1 pathway could be a promising therapeutic strategy for CC.

  • Open Access

    Cervical Cancer Screening and Prevention

    by Mei Li, Zi-Ling Yang, Zhen-Yu Chen, Liu Jiang, Shi-Yuan Hong

    Cervical cancer has caused numerous deaths in women worldwide over the past few decades. It is a serious clinical problem that needs to be solved, though its morbidity and mortality have declined in recent years. The current treatments against cervical cancer are hysterectomy, radiotherapy, and chemotherapy, with certain limitations. Meanwhile, progress has been made in the screening and prevention of cervical cancer, focusing on human papillomavirus (HPV) infection, which is considered a necessary but insufficient cause. This review summarizes our current knowledge of screening and prevention of cervical cancer and its relation to HPV.


  • Open Access

    Global characterization of extrachromosomal circular DNAs in advanced high grade serous ovarian cancer

    by Yixuan Cen, Yifeng Fang, Yan Ren, Shiyuan Hong, Weiguo Lu, Junfen Xu

    High grade serous ovarian cancer (HGSOC) is the most aggressive subtype of ovarian cancer and HGSOC patients often appear with metastasis, leading to the poor prognosis. Up to date, the extrachromosomal circular DNAs (eccDNAs) have been shown to be involved in cancer genome remodeling but the roles of eccDNAs in metastatic HGSOC are still not clear. Here we explored eccDNA profiles in HGSOC by Circle-Sequencing analysis using four pairs of primary and metastatic tissues of HGSOC patients. Within the differentially expressed eccDNAs screened out by our analysis, eight candidates were validated by outward PCR and qRT-PCR analysis. Among them, DNMT1circle10302690-10302961 was further confirmed by FISH assay and BaseScope assay, as the most significantly down-regulated eccDNA in metastatic tumors of HGSOC. Lower expression of DNMT1circle10302690-10302961 in both primary and metastatic tumors was associated with worse prognosis of HGSOC. Taken together, our finding firstly demonstrated the eccDNAs landscape of primary and metastatic tissues of HGSOC. The eccDNA DNMT1circle10302690-10302961 can be considered as a potential biomarker or a therapeutically clinical target of HGSOC metastasis and prognosis.


  • Open Access

    Arsenic compound sensitizes homologous recombination proficient ovarian cancer to PARP inhibitors

    by Junfen Xu, Yuanming Shen, Conghui Wang, Sangsang Tang, Shiyuan Hong, Weiguo Lu, Xing Xie, Xiaodong Cheng

    The poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors show survival benefits in ovarian cancer patients withBRCA1/2mutation or homologous recombination (HR) deficiency, but only limited efficacy in HR-proficient ones. Another drug, arsenic trioxide (ATO) or arsenic drug (RIF), exerts antitumor effects via inducing DNA damage. Here, we investigated the combined therapeutic effects of the PARP inhibitors and the arsenic compound in HR-proficient ovarian cancer. The combined treatment of niraparib, olaparib, or fluazolepali with ATO showed a significant suppression in tumor cell viability and colony formation. The drug treatment also induced synergistic inhibition of cell proliferation and DNA damage, and acceleration of cell apoptosis in two HR-proficient ovarian cancer cell lines SKOV3 and CAOV3, either by simultaneous or sequential administration. The mechanism underlying these synergistic effects were reflected by the significantly increased ratio of cleaved-PARP/total PARP and decreased ratio of p-AKT/total AKT. Consistently, the combination of olaparib with RIF synergistically reduced the tumor growth in mouse xenograft models. In conclusion, the arsenic compound greatly sensitizes HR-proficient ovarian cancer cells to the PARP inhibitors, and our findings provide an evidence for the clinical treatment development of this combination in HR-proficient ovarian cancer patients.


  • Open Access

    Topoisomerase 2β Induces DNA Breaks To Regulate Human Papillomavirus Replication

    by Paul Kaminski, Shiyuan Hong, Takeyuki Kono, Paul Hoover, Laimonis Laimins

    High-risk human papillomaviruses (HPVs) infect epithelial cells and induce viral genome amplification upon differentiation. HPV proteins activate DNA damage repair pathways by inducing high numbers of DNA breaks in both viral and cellular DNAs.


  • Open Access

    Topoisomerase 2β induces DNA breaks to regulate human papillomavirus replication

    by Paul Kaminski, Shiyuan Hong, Takeyuki Kono, Paul Hoover, Laimonis Laimins

    Topoisomerases regulate higher order chromatin structures through the transient breaking and re-ligating of one or both strands of the phosphodiester backbone of duplex DNA. TOP2β is a type II topoisomerase that induces double strand DNA breaks at topological-associated domains (TADS) to relieve torsional stress arising during transcription or replication. TADS are anchored by CTCF and SMC1 cohesin proteins in complexes with TOP2β. Upon DNA cleavage a covalent intermediate DNA-TOP2β (TOP2βcc) is transiently generated to allow for strand passage. The tyrosyl-DNA phosphodiesterase TDP2 can resolve TOP2βcc but failure to do so quickly can lead to long-lasting DNA breaks. Given the role of CTCF/SMC1 proteins in the HPV life cycle we investigated if TOP2β proteins contribute to HPV pathogenesis. Our studies demonstrated that levels of both TOP2β and TDP2 were substantially increased in cells with high risk HPV genomes and this correlated with high amounts of DNA breaks. Knockdown of TOP2β with shRNAs reduced DNA breaks by over 50% as determined through COMET assays. Furthermore this correlated with substantially reduced formation of repair foci such as γH2AX, pCHK1 and pSMC1 indicative of impaired activation of DNA damage repair pathways. Importantly, knockdown of TOP2β also blocked HPV genome replication. Our previous studies demonstrated that CTCF /SMC1 factors associate with HPV genomes at sites in the late regions of HPV31 and these correspond to regions that also bind TOP2β. This study identifies TOP2β as responsible for enhanced levels of DNA breaks in HPV positive cells and as a regulator of viral replication.